Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand

HLS Therapeutics

12/08/2026 11:41

Overview
Canada pharmaceutical firm's Q2 revenue grew 3.5% yr/yr, beating analyst expectations
Adjusted EBITDA declined in Q2 due to investment in NILEMDO launch
Company repurchased 339,880 shares under NCIB, returning C$1.4 mln to shareholders

Outlook
HLS reaffirms 2026 revenue guidance of $56-60 mln, representing mid-single-digit percentage growth
Company maintains 2026 Adjusted EBITDA forecast of $18.5-21 mln, reflecting NILEMDO launch costs
Company says margins expected to expand as NILEMDO revenue ramps up in H2 2026

Result Drivers
CARDIOVASCULAR PORTFOLIO - 25% yr/yr net sales growth in cardiovascular drugs, led by Vascepa and NILEMDO, drove Q2 revenue gains
NILEMDO LAUNCH INVESTMENT - Incremental investment in NILEMDO launch led to higher operating expenses and lower Adjusted EBITDA
CLOZARIL STABILIZATION - Canadian Clozaril sales declined 1% but patient base grew for five consecutive months, indicating business stabilization

Company press release: ID:nCNWnBjj6a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$14.67 mln
$14.47 mln (3 Analysts)
Q2 Loss Per Share
 
$0.03
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for HLS Therapeutics Inc is C$6.00, about 56.7% above its August 11 closing price of C$3.83

Reuters Recommended Reads
Aug 11 - Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage
Aug 10 - Canada's Medexus Q1 revenue beats on GRAFAPEX strength
Aug 11 - Canada's Eupraxia Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)